PDL BioPharma, a biotech that’s recently been forced to sell a number of its key assets, has announced some positive news in the form of a deal with Bristol-Myers Squibb for PDL’s Phase I multiple myeloma candidate, elotuzumab. PDL will receive US$30 M upfront and potential milestones that could total US$680 M if the product is successfully developed and marketed.